YOLFTbeta
WuXi XDC Cayman Inc.

WuXi XDC Cayman Inc.

L74 · F · Healthcare / Diagnostics & Research

7.90EUR-0.30 (-3.66%)

Price History

Full chart

Market Stats

Previous Close8.20
Open7.85
Day Range7.85 – 7.90
52-Week Range4.90 – 9.15
Volume0
Market Cap11.40B
P/E (TTM)60.00
Forward P/E33.11
EPS0.15
Dividend Yield0.00%
Beta-0.76
50-Day Avg7.59
200-Day Avg6.69

About

WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. Additionally, the company engages in the research and development, manufacturing, and marketing of anti-tumor drugs. WuXi XDC Cayman Inc. has a strategic collaboration with Earendil Labs; and Akari Therapeutics. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEODr. Jincai Li Ph.D.
  • Employees3.63K
  • HeadquartersNo. 11 Xinhui Ring Road, Wuxi, China, Germany
  • Websitehttps://wuxixdc.com

Leadership

  • Dr. Jincai Li Ph.D.CEO & Executive Director · b. 1973
  • Mr. Xiaojie XiCFO & Executive Director · b. 1976
  • Mr. Jingwei ZhangCOO & Executive Director · b. 1969
  • Dr. Meiying ZhuChief Technology Officer · b. 1966
  • Ms. Yuan FangJoint Company Secretary, Head of IR, Capital Markets, Corporate Communication and Public Affairs
  • Ms. Man Nar ChungJoint Company Secretary
  • Dr. Jianjun LuoVice President · b. 1968

Financials

Income Statement

Currency: CNY2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue311.13M990.42M2.12B4.05B5.94B
Growth (%)-+218.33%+114.44%+90.80%+46.69%
Cost of Revenue197.64M729.34M1.56B2.81B3.80B
Gross Profit113.49M261.08M559.56M1.24B2.14B
Gross Margin36.48%26.36%26.35%30.60%35.99%
Operating Expense53.36M119.41M157.66M291.31M468.59M
Operating Income60.13M141.67M401.90M948.53M1.67B
Operating Margin19.33%14.30%18.92%23.41%28.11%
EBITDA-229.53M419.87M1.33B1.90B
EBITDA Margin-23.17%19.77%32.90%31.98%
Net Income54.93M155.73M283.54M1.07B1.48B
Net Income Margin17.65%15.72%13.35%26.40%24.91%
R&D13.81M33.84M76.87M99.96M147.21M
R&D as % of Total Revenue4.44%3.42%3.62%2.47%2.48%
Interest Expense493.00K2.92M742.00K3.21M16.97M
Interest Expense % of Total Revenue0.16%0.29%0.03%0.08%0.29%

Balance Sheet

Currency: CNY2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets879.75M2.50B6.74B9.12B14.44B
Total Liabilities858.87M1.02B1.28B2.48B3.71B
Total Equity20.88M1.48B5.45B6.64B10.73B
Cash26.32M334.97M4.05B1.93B1.51B

Cash Flow

Currency: CNY2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow59.14M251.82M332.85M717.22M1.78B
Capital Expenditure51.91M201.38M539.36M1.51B1.26B
Free Cash Flow7.23M50.43M-206.51M-787.95M523.52M
FCF to OCF12.22%20.03%-62.05%-109.86%29.36%

Earnings

Report DateMar 29, 2027
EPS Estimate-
EPS Actual-
Surprise-
TimingAfter-hours

Key Statistics & Ratios

Market Cap11.40B
Enterprise Value10.66B
Trailing P/E60.00
Forward P/E33.11
Price / Sales1.64
Price / Book7.57
EPS0.15
Book Value1.09
Revenue (TTM)6.94B
Gross Profit (TTM)2.54B
EBITDA2.15B
Profit Margin22.38%
Operating Margin29.63%
Return on Equity16.33%
Return on Assets9.32%
Shares Outstanding1.27B
Shares Float443.34M
Beta-0.76
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%